Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lineage Cell Therapeutics reports successful Q4, eyes strategic partnerships

Lineage Cell Therapeutics is advancing with promising programs like OpRegen, focusing on financial discipline and milestone achievements to drive shareholder value in 2023.
Despite net losses in 2022, Lineage's strong cash position, successful clinical outcomes, and strategic partnerships position the company for growth and leadership in cell therapy.

Lineage Cell Therapeutics reports progress in Q1 despite financial challenges

Lineage Cell Therapeutics showcased progress in OpRegen's clinical findings and financial performance in Q1 2023.
The company faces challenges in financials and market education but holds strengths in strategic partnerships and therapeutic advantages.
Opportunities lie in market positioning, collaborations, and continued innovation to drive growth and market adoption for Lineage's therapies.

Lineage Cell Therapeutics reports stable finances and advances key programs

Lineage Cell Therapeutics shows financial stability with strong cash reserves and a strategic focus on advancing key pipeline programs.
Despite challenges in patient enrollment and cell delivery, the company remains innovative and adaptable in exploring gene therapy solutions.
Positive FDA feedback on the OPC1 program and ongoing exploration of partnerships and advancements position Lineage for future growth and success.

Lineage Cell Therapeutics reports strong Q3 performance and eyes growth

Lineage Cell Therapeutics demonstrated financial stability, innovation in cell therapy, and progress in regenerative medicine programs during Q3 2023.
Challenges include study completion, safety concerns, enrollment trends, and strategic resource allocation for future growth.
Opportunities lie in market expansion, collaborations in neurology, therapeutic advancements, and regulatory success for the company.
Overall, Lineage Cell Therapeutics is positioned for growth through strategic partnerships and advancements in regenerative medicine.

Lineage Cell Therapeutics reports stable finances and program advancements

Lineage Cell Therapeutics showcased financial stability, program advancements, and strategic decisions in the Q4 2023 earnings call, emphasizing progress in OpRegen and OPC1 programs.
While facing challenges in managing expenses and uncertainties in program timelines, the company highlighted opportunities in partnerships, patient inclusion, and innovation for future growth.
Analyst questions focused on clinical outcomes, financing decisions, and program updates, reflecting investor interest in OpRegen program advancements and market potential.

Lineage Cell Therapeutics reports Q1 results, highlights partner support

Lineage Cell Therapeutics' Q1 2024 performance reflects revenue challenges but highlights strong partner support and operational preparedness.
The company faces financial losses amid investments in R&D but showcases a commitment to strategic growth and long-term success.
Challenges in revenue generation and data validation are balanced by opportunities in clinical trial efficiency, market demand, and therapeutic expansion.
Overall, Lineage's focus on innovation, partnerships, and operational readiness positions it for potential growth and success in the cell therapy space.

Lineage Cell Therapeutics extends cash runway, advances key programs

Lineage Cell Therapeutics reported financials for Q3 2024, extending cash runway and showcasing progress in key programs.
Strengths include advancements in OpRegen and ReSonance programs, with a strategic focus on manufacturing and partnerships.
Challenges lie in financial performance, maintaining cash discipline, and meeting study endpoints, while opportunities arise from collaborations and program advancements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020

Lineage Cell Therapeutics Is A High-Risk But High-Reward Opportunity To Consider

Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q1 2020 Results - Earnings Call Transcript

Is  (LCTX) Outperforming Other Medical Stocks This Year?

Is Lineage Cell Therapeutics (LCTX) Outperforming Other Medical Stocks This Year?

On Lineage Cell's (LCTX) Q1 earnings call, investor focus will be on its progress with the pipeline candidate OpRegen, currently being developed for treating dry AMD, as well as other pipeline updates.

Lineage Cell (LCTX) to Post Q1 Earnings: What's in the Cards?

As of late, it has definitely been a great time to be an investor Lineage Cell Therapeutics

Will Lineage Cell Therapeutics Continue to Surge Higher?

Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Lineage Cell (LCTX) Q1 Earnings Expected to Decline

Lineage Cell Therapeutics, Inc. (LCTX) has been struggling lately, but the selling pressure may be coming to an end soon.

Lineage Cell Therapeutics Sees Hammer Chart Pattern: Time to Buy?

Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q4 2019 Results - Earnings Call Transcript

Lineage Cell (LCTX) delivered earnings and revenue surprises of 57.14% and 108.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates

Lineage Cell (LCTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

BioTime, Inc. (LCTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

BioTime, Inc. (LCTX) Upgraded to Strong Buy: Here's Why

Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q3 2019 Results - Earnings Call Transcript

Lineage Cell Therapeutics has suffered a marked decreasing trend in recent years.

OpRegen: The Great Asset Of Lineage Cell Therapeutics

BioTime, Inc. (BTX) CEO Brian Culley on Q2 2019 Results - Earnings Call Transcript

BioTime (BTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioTime (BTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

BioTime, Inc. (BTX) CEO Brian Culley on Q1 2019 Results - Earnings Call Transcript

BioTime (BTX) delivered earnings and revenue surprises of 600.00% and 40.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

BioTime (BTX) Tops Q1 Earnings and Revenue Estimates

Will BioTime (BTX) Report Negative Q1 Earnings? What You Should Know

BioTime (BTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BioTime (BTX) Upgraded to Strong Buy: Here's What You Should Know

BioTime, Inc. (BTX) CEO Brian Culley on Q4 2018 Results - Earnings Call Transcript

News for Lineage Cell Therapeutics Inc Stock (LCTX)